Sign up to save your podcasts
Or
Share Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2525 ratings
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
JAMA Editors' Summary
136 Listeners
AFP: American Family Physician Podcast
695 Listeners
JAMA Clinical Reviews
495 Listeners
JACC This Week
170 Listeners
Diabetes Core Update
101 Listeners
This Week in Cardiology
885 Listeners
The Bob Harrington Show
13 Listeners
One-on-One with Eric Topol
17 Listeners
Mayo Clinic Talks
291 Listeners
Frankly Speaking About Family Medicine
260 Listeners
The Curbsiders Internal Medicine Podcast
3,341 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Freely Filtered, a NephJC Podcast
173 Listeners
Medicine and the Machine
61 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
429 Listeners